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EDITORIAL COMMENT

Risk Scores–Medical Derivatives*
Ronald S. Freudenberger, MD, MBA

“Derivatives are like sex. It’s not who we’re

large, published randomized trials or meta-analyses

sleeping with, it’s who they’re sleeping with

to determine the b-coefﬁcients (natural log of the haz-

that’s the problem.”

ard ratio) for adding the medication/device to a pa-

F

—Warren Buffett (1)
inancial derivatives are contracts that derive
their value from the use of underlying assets
as foundation and building blocks to out-

comes. Similarly, medical risk scores derive their
values from the underlying derivation cohorts. Use
of this approach in both cases confers aggregated
risk; therefore, the further one travels from the original cohort or underlying asset, the greater likelihood
of inaccuracy and risk. Using risk scores to predict
outcomes in heart failure (HF) has become the holy
grail of the HF investigator. Between 1994 and 2012,
there were >117 different models described in 55 papers aiming to predict mortality or HF hospitalizations (2). Most risk scores and predictive models are
derived from cohorts taken from clinical trials, which
represent a very select population that is difﬁcult to
generalize to the individual patient. Often, the trials
that make up the cohort are from a different population and era for which the model is intended to predict outcomes. For example, the commonly used
Seattle Heart Failure Model was developed by
analyzing 1 cohort of 1,125 subjects in the Prospective
Randomized Amlodipine Survival Evaluation study,
published in 1996 (3); however, because of its period
of study, it had limited use of contemporary therapies
(i.e.,

beta-blockers,

deﬁbrillators,

and

implantable

aldosterone

cardioverter-

antagonists).

To

accommodate for these deﬁciencies, the Seattle Heart
Failure Model authors decided that “for these medications and devices, beneﬁts were estimated from

tient’s

regimen.”

In

spite

of

these

multiple

derivations from different cohorts in different eras
and estimates of beneﬁts of game-changing therapies,
the model performed fairly well in 5 validation cohorts.
This model was subsequently used in further derivations of this derivative (4–7), including 1 to predict beneﬁts from implantable cardioverter-deﬁbrillators (8), 1
of the b -coefﬁcients added to the original model.
Hence, one can certainly see the danger of generalizing
derivatives of derivatives to an individual patient.
Therefore, to ensure the validity of a model, 4 aspects must maintain integrity: 1) the derivation of the
original cohort; 2) its generalizability; 3) its ability to
discriminate; and 4) accurate calibration. Discrimination relates to the ability of the model to differentiate
those patients who had events from those who did not.
This is commonly assessed using the C-statistic, which
is equivalent to the area under the receiver-operating
characteristic curve (9). The calibration and “goodness-of-ﬁt” of a model involve investigating how close
the values predicted by the model are to the actual
observed values (i.e., does the model work?).
SEE PAGE 727

In this issue of the Journal, the paper by Ferriera
et al. (10) seems to reﬂect that, having exhausted the
avenue of mortality and hospitalization models, we
are at the start of a new approach to mining the data,
this time, in search of answers relating to stroke
(editorialist included).
The authors of this paper report of a pooled analysis of several large clinical trials involving acute
myocardial infarction, patients with HF or moderate
left ventricular dysfunction, and systolic dysfunction.
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The purpose of this analysis is to identify risk factors
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additional dataset used for external validation.

may have affected the validity of the stroke risk

The validation cohort includes patients with acute

model.

myocardial infarction with signs and symptoms of

The utility of CHA 2S2DS 2-VASc (congestive heart

congestive HF or diabetes mellitus without signs or

failure, hypertension, age $75 [doubled], diabetes,

symptoms of congestive HF (11). The discriminatory

stroke [doubled], vascular disease, age 65–74, and

ability of this model to predict death or stroke

sex category [female]) predicting stroke even in the

(c-index) is 0.67. Most authors deem model discrim-

absence of atrial ﬁbrillation was recently reported

ination as poor if the C-statistic is between 0.50 and

(14) by retrospectively evaluating patients who pre-

0.70, modest if between 0.70 and 0.80, and accept-

sented with stroke and applying the pre-stroke

able if >0.80 (12). Calibration as tested and reported

CHA2S2DS 2-VASc score. The current study is the

in this model is good with the observed 3-year stroke

only 1 that identiﬁes post MI, HF patients without

event rate increasing steeply for each category of the

atrial ﬁbrillation and provides a score with good

risk score (1.8%, 2.9%, 4.1%, 5.6%, 8.3%, and 10.9%,

calibration.

respectively). This well-constructed risk model is the

Given the inherent difﬁculty in using clinical trials

only such model developed to guide clinicians

as the derivation cohort in risk models that may be

conducting clinical trial on strategies to enhance the

clinically useful, Califf has pointed out that the in-

design of future studies in this population.

formation contained in the electronic medical record

In this paper, the primary endpoint is stroke (death

may provide a basis for investigating a more hetero-

was a competing risk). The term “stroke” is not

geneous population that can be used to develop bet-

consistently deﬁned in clinical practice or assessments

ter tools with greater generalizability (15). Greater

of public health (13). As with acute myocardial infarc-

generalizability may result in our ability to apply

tion, there was no “universal” deﬁnition of stroke until

these tools for population health management to

recently. The term is neither deﬁned nor adjudicated

identify those that may require more intensive

in many HF clinical trials, particularly when stroke is

observation and subsequent clinical decision making,

not a primary endpoint. Rather, it is often deﬁned by

rather than its applicability to individual patients.

the patient, family member, study nurse, or cardiolo-

These risk tools may be helpful but certainly must be

gist, so this endpoint is derived from case report forms,

used with caution and proper training as with any

which is yet another derivation. Fortunately, in this

other tool. As tools, they should be used to help

report, the authors indicate that all stroke endpoints

inform clinical decision-making, but not become the

were deﬁned and adjudicated, representing a signiﬁ-

absolute arbiter.

cant strength of this analysis.
The authors correctly note that in this analysis,
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